These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
145 related items for PubMed ID: 11689583
1. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. Leonard R, Hardy J, van Tienhoven G, Houston S, Simmonds P, David M, Mansi J. J Clin Oncol; 2001 Nov 01; 19(21):4150-9. PubMed ID: 11689583 [Abstract] [Full Text] [Related]
2. Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer. Terwogt JM, Mandjes IA, Sindermann H, Beijnen JH, ten Bokkel Huinink WW. Br J Cancer; 1999 Mar 01; 79(7-8):1158-61. PubMed ID: 10098751 [Abstract] [Full Text] [Related]
11. Miltefosine in recurrent cutaneous breast cancer. Clive S, Leonard RC. Lancet; 1997 Mar 01; 349(9052):621-2. PubMed ID: 9057742 [No Abstract] [Full Text] [Related]
12. Loco-regional control of cutaneous metastases of malignant melanoma by treatment with miltefosine (Miltex). Ragnarsson-Olding B, Djureen-Mårtensson E, Månsson-Brahme E, Hansson J. Acta Oncol; 2005 Mar 01; 44(7):773-7. PubMed ID: 16227173 [No Abstract] [Full Text] [Related]
13. 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancers. Eilender D, LoRusso P, Thomas L, McCormick C, Rodgers AH, Hooper CL, Tornyos K, Krementz ET, Parker S, Morgan LR. Cancer Chemother Pharmacol; 2006 Jun 01; 57(6):719-26. PubMed ID: 16184382 [Abstract] [Full Text] [Related]
14. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Unger C, Sindermann H, Peukert M, Hilgard P, Engel J, Eibl H. Prog Exp Tumor Res; 1992 Jun 01; 34():153-9. PubMed ID: 1438798 [No Abstract] [Full Text] [Related]
15. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay MA, Rao S, Pacaud LB, Taran T, Slamon D. Lancet Oncol; 2015 Jul 01; 16(7):816-29. PubMed ID: 26092818 [Abstract] [Full Text] [Related]
16. Miltefosine for new world cutaneous leishmaniasis. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H. Clin Infect Dis; 2004 May 01; 38(9):1266-72. PubMed ID: 15127339 [Abstract] [Full Text] [Related]
17. Treatment of New World cutaneous leishmaniasis with miltefosine. Soto J, Berman J. Trans R Soc Trop Med Hyg; 2006 Dec 01; 100 Suppl 1():S34-40. PubMed ID: 16930649 [Abstract] [Full Text] [Related]
19. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G. J Clin Oncol; 2000 Apr 01; 18(7):1399-411. PubMed ID: 10735887 [Abstract] [Full Text] [Related]
20. [Multiple cutaneous plasmocytoma treated with topical applications of miltefosine]. Viseux V, Schoenlaub P, Danhier S, Vilque JP, Plantin P. Ann Dermatol Venereol; 2004 Feb 01; 131(2):204-5. PubMed ID: 15026752 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]